Chronic malaria exposure has been proposed to modulate immune function, but its long-term effects on antibody-mediated responses to unrelated pathogens remain poorly defined. Whether these effects ...

Scientists have found a way to transform hard-to-treat tumors into targets for the immune system. Using two protein stimulators, they activated strong T-cell and B-cell responses and built immune ...

The evolution of immunotherapy, featuring CAR-T cells and senolytics, highlights potential in cancer treatment and challenges ...

Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly ...

When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market ...

Australian Patent Grant and European Intent to Grant strengthen Pilatus' leadership in metabolic checkpoint modulation to reprogram regulatory T cells (Tregs) and enhance anti-tumor immunity Pilatus ...

SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), ...